Math Calculator 2.3.1 with Keygen Activation



1. Bhutto IA, McLeod DS, Hasegawa T, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Experimental Eye Research. 2006;82(1):99–110. [PMC free article] [PubMed]

2. Wong T, Chakravarthy U, Klein R, et al. The Natural History and Prognosis of Neovascular age-related macular degeneration. A Systematic Review of the Literature and Meta-analysis. Ophthalmology. 2008;115(1):116.e1–126.e1. [PubMed]

3. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. American Journal of Ophthalmology. 1996;122(3):393–403. [PubMed]

4. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Investigative Ophthalmology and Visual Science. 1996;37(9):1929–1934. [PubMed]

5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine. 2006;355(14):1419–1431. [PubMed]

6. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England Journal of Medicine. 2006;355(14):1432–1444. [PubMed]

7. Owsley C. Contrast sensitivity. Ophthalmology Clinics of North America. 2003;16(2):171–177. [PubMed]

8. Rubin GS, Bandeen-Roche K, Huang GH, et al. The association of multiple visual impairments with self-reported visual disability: SEE project. Investigative Ophthalmology and Visual Science. 2001;42(1):64–72. [PubMed]

9. Koch KR, Muether PS, Hermann MM, Hoerster R, Kirchhof B, Fauser S. Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD. Graefe's Archive for Clinical and Experimental Ophthalmology. 2012;250:201–209. [PubMed]

10. Feigl B, Greaves A, Brown B. Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity. Journal of Clinical Ophthalmology. 2007;1:167–175. [PMC free article] [PubMed]

11. Loshin DS, White J. Contrast sensitivity. The visual rehabilitation of the patient with macular degeneration. Archives of Ophthalmology. 1984;102(9):1303–1306. [PubMed]

12. Sandberg MA, Gaudio AR. Slow photostress recovery and disease severity in age-related macular degeneration. Retina. 1995;15(5):407–412. [PubMed]

13. Parravano M, Oddone F, Tedeschi M, et al. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results. Retina. 2010;30(7):1017–1024. [PubMed]

14. Kiss CG, Geitzenauer W, Simader C, Gregori G, Schmidt-Erfurth U. Evaluation of ranibizumab-induced changes in high- resolution optical coherence tomographic retinal morphology and their impact on visual function. Investigative Ophthalmology and Visual Science. 2009;50(5):2376–2383. [PubMed]

15. Midena E, Radin PP, Pilotto E, Ghirlando A, Convento E, Varano M. Fixation pattern and macular sensitivity in eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. A Microperimetry Study. Seminars in Ophthalmology. 2004;19(1-2):55–61. [PubMed]

16. Ozdemir H, Karacorlu M, Senturk F, Karacorlu SA, Uysal O. Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration. Acta Ophthalmologica. 2012;90:71–75. [PubMed]

17. Das R, Shi Y, Silvestri G, Chakravarthy U. Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to lucentis therapy. Retina. 2009;29(7):1013–1018. [PubMed]

18. Ergun E, Maár N, Radner W, Barbazetto I, Schmidt-Erfurth U, Stur M. Scotoma size and reading speed in patients with subfoveal occult choroidal neovascularization in age-related macular degeneration. Ophthalmology. 2003;110(1):65–69. [PubMed]

19. Stifter E, Weghaupt H, Benesch T, Thaler A, Radner W. Discriminative power of reading tests to differentiate visual impairment caused by cataract and age-related macular degeneration. Journal of Cataract and Refractive Surgery. 2005;31(11):2111–2119. [PubMed]

20. Kloos P, Bernasconi P, Estermann S, Bachmann B, Rutishauser Y, Thölen A. Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration. Klinische Monatsblatter fur Augenheilkunde. 2008;225(5):385–391. [PubMed]

21. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology. 2007;125(11):1460–1469. [PubMed]

22. Suńer IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Investigative Ophthalmology and Visual Science. 2009;50(8):3629–3635. [PubMed]

23. Lamoureux EL, Mitchell P, Rees G, et al. Impact of early and late age-related macular degeneration on vision-specific functioning. British Journal of Ophthalmology. 2011;95:666–670. [PubMed]

24. Singh RP, Fu EX, Smith SD, Williams DR, Kaiser PK. Predictive factors of visual and anatomical outcome after intravitreal bevacizumab treatment of neovascular age-related macular degeneration: an optical coherence tomography study. British Journal of Ophthalmology. 2009;93(10):1353–1358. [PubMed]

25. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. American Journal of Ophthalmology. 2007;144(6):850.e4–857.e4. [PubMed]

26. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. American Journal of Ophthalmology. 2009;148(1):43–58. [PubMed]

27. Hohberger B, Laemmer R, Adler W, Juenemann AGM, Horn FK. Measuring contrast sensitivity in normal subjects with OPTEC 6500: influence of age and glare. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2007;245(12):1805–1814. [PubMed]

28. Rohrschneider K, Springer C, Bültmann S, Völcker HE. Microperimetry—comparison between the micro perimeter 1 and scanning laser ophthalmoscope—fundus perimetry. American Journal of Ophthalmology. 2005;139(1):125–134. [PubMed]

29. Stifter E, König F, Lang T, et al. Reliability of a standardized reading chart system: variance component analysis, test-retest and inter-chart reliability. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2004;242(1):31–39. [PubMed]

30. Massin P, Vicaut E, Haouchine B, Erginay A, Paques M, Gaudric A. Reproducibility of retinal mapping using optical coherence tomography. Archives of Ophthalmology. 2001;119(8):1135–1142. [PubMed]

31. Loughman J, Akkali MC, Beatty S, et al. The relationship between macular pigment and visual performance. Vision Research. 2010;50(13):1249–1256. [PubMed]

32. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study. Ophthalmology. 2009;116(1):57–65. [PubMed]

33. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. American Journal of Ophthalmology. 2007;143(4):566–583. [PubMed]

34. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA Study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(10):1868–1875. [PubMed]

35. Williams TA, Blyth CP. Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. Eye. 2011;25:1617–1621. [PMC free article] [PubMed]

36. Monés J, Rubin GS. Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration. Eye. 2005;19(11):1142–1150. [PubMed]

37. Scott IU, Feuer WJ, Jacko JA. Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration. American Journal of Ophthalmology. 2002;133(3):350–357. [PubMed]

38. Rubin GS, Roche KB, Prasada-Rao P, Fried LP. Visual impairment and disability in older adults. Optometry and Vision Science. 1994;71(12):750–760. [PubMed]

39. Kuyk T, Elliott JL. Visual factors and mobility in persons with age-related macular degeneration. Journal of Rehabilitation Research and Development. 1999;36(4):303–312. [PubMed]

40. Varano M, Scassa C. Scanning laser ophthalmoscope microperimetry. Seminars in Ophthalmology. 1998;13(4):203–209. [PubMed]

41. Alexander P, Mushtaq F, Osmond C, Amoaku W. Microperimetric changes in neovascular age-related macular degeneration treated with ranibizumab. Eye. 2012;26:678–683. [PMC free article] [PubMed]

42. Frennesson C, Nilsson UL, Peebo BB, Nilsson SEG. Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration. Acta Ophthalmologica. 2010;88(4):420–425. [PubMed]



865